Close menu




March 11th, 2021 | 07:30 CET

Compass Pathways, Canopy Growth, PsyBio Therapeutics - Cannabis or psilocybin?

  • Biotechnology
Photo credits: pixabay.com

Cannabis stocks have been a bit forgotten after an early-year rally caused a 500% increase in some cases. Most stocks have already corrected back up 50% from the top and have been running more sideways recently. Speculation in psychoactive substances has recently shifted to a new industry, the mushroom applications around psilocybin. These substances are said to treat particular forms of depression, a fact that is becoming more explosive against the backdrop of increasing loneliness due to Covid lockdowns. Let's take a look at some prominent representatives.

time to read: 3 minutes | Author: André Will-Laudien
ISIN: GB00BD6K4575 , CA1380351009 , CA6936971044

Table of contents:


    Canopy Growth - Neatly under the radar

    Canopy Growth is a global leader in cannabis and cannabinoid-based consumer products that aim to improve lives, end prohibition and empower communities by unlocking the full potential of cannabis.

    The Company follows a continuous learning process from the insights and experiences of hemp product users. It offers diverse product variants in the form of dry flowers, oils, softgel capsules, beverages, and specialized vaporizer devices. Canopy Growth is undoubtedly one of the most innovative among publicly traded cannabis stocks. However, the pivotal point is the US market, which is being addressed by Canopy but is ultimately in the hands of US suppliers such as Curaleaf or Tilray. Here, full legalization of cannabis is expected in 2021/2022. The Canadians will have a hard time growing sustainably in the US.

    The beginning of 2021 saw a century rally across the industry. Canopy's shares rose from CAD 18 to CAD 70 within 3 months. However, the value corrected sharply to prices around CAD 40, which can go even further. Tilray shows the same chart, so we expect further declining quotations. To find a possible reason for the current downturn, a look at the second psychedelic wave is worthwhile.

    Compass Pathways - The first mover in psilocybin

    Compass Pathways is a UK mental health Company primarily dedicated to accelerating patient access to evidence-based innovations in the human psyche. Its focus is on improving the lives of those suffering from mental distress who cannot find help under currently available treatments. Compass thus works with entirely new agents and uses new therapeutic methods.

    Compass has pioneered the development of a new model of psilocybin therapy that uses a proprietary formulation of synthetic psilocybin (COMP360) in conjunction with psychological, therapeutic support. COMP360 has been designated by the US Food and Drug Administration (FDA) as a "Breakthrough Therapy for Treatment-Resistant Depression (TRD)." A Phase IIb clinical trial of psilocybin therapy for TRD is currently underway at 22 sites in Europe and North America. If the results are positive, psilocybin therapies are likely to have broad application in TRD.

    High costs still mark Compass' overall numbers. Accordingly, the net loss for the 12 months ended Dec. 31, 2020, was USD 60.3 million, with research and development (R&D) expenses reaching USD 23.4 million. Compass stock is one of the beacons of hope for an entire industry that is in the process of re-establishing itself. However, with a market capitalization of USD 1.6 billion, the first valuation leap has already been made.

    PsyBio Therapeutics Corp. - Brand new on the list

    A brand new stock is PsyBio Therapeutics Corp. from Florida. PsyBio is a biotechnology Company developing novel formulations of psychoactive drugs produced by genetically engineered bacteria to treat mental and other disorders. The team is highly skilled in drug innovation based on synthetic biology.

    Research and development is currently focused on naturally occurring tryptamines found in various types of "magic mushrooms," as well as other tryptamines and phenethylamines and combinations thereof. The Company is also researching and developing new molecular structures that do not occur in nature but could have unique therapeutic properties. Overall, research is still extensive and under-researched, which naturally gives the entire industry great future significance. As with cannabinoids, the so-called "entourage effect" is also used with psilocybin.

    PsyBio, in collaboration with Albany Molecular Research Inc. (AMRI), a leading global provider of advanced contract R&D solutions, has begun building its proprietary biosynthetic formulation of psilocybin. AMRI has already completed Phase I of this process, including the necessary technology transfer activities and analytical methods. Further progress and announcements are expected to be made here in the coming weeks.

    PsyBio shares were listed on the Toronto Stock Exchange at the end of February and as per today in Frankfurt. Its market capitalization with its about 113 million listed and unlisted shares is still a manageable CAD 40 million. Remembering the gigantic 2018-2021 cannabis bull market, this new industry is one to keep an eye on.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author



    Related comments:

    Commented by Nico Popp on November 30th, 2022 | 13:33 CET

    Advances in the fight against cancer: Arcus Biosciences, Gilead Sciences, Defence Therapeutics, BioNTech

    • Biotechnology
    • Covid19
    • Cancer

    Research studies from 2020 show that 72% of Germans fear cancer. However, very few people want to admit to these fears. But precisely because the subject is a big taboo, it is worth looking at the latest achievements in research. Many companies worldwide have long been fighting the epidemic - and making astonishing progress. Just recently, a US biotech announced encouraging study results. Other companies have yet to launch promising studies. We provide an overview and outline opportunities from an investor's perspective.

    Read

    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

    Read

    Commented by Fabian Lorenz on November 24th, 2022 | 12:40 CET

    New year, rising prices? BASF, BioNTech and Manuka Resources - Shares in check

    • Mining
    • Commodities
    • Biotechnology
    • chemicals

    As the stock market year 2022 draws to a close, we look ahead to 2023. New year, rising prices? That is what many stock market players are hoping for. The chances are that we will see rising indices again with the end of interest rate hikes in the coming year. Today, we look at three companies likely to attract attention in 2023. At BioNTech, the research pipeline is full to bursting, and there are numerous study results to come. BASF is attractive due to its low valuation and high dividend yield. However, analysts warn of a write-off risk. Manuka Ressources convinces with a profitable core business, and an exciting project in the field of critical raw materials could lead to a revaluation.

    Read